A new trend in skincare is blurring the line between professional treatments and at-home maintenance. Instead of seeing a facial as a one-time event, more brands now treat the clinic and the bathroom mirror as parts of the same routine, designed to work together and keep results going after the appointment ends.
The article says the market has caught up to that idea. Global home skincare was valued at about $135 billion in 2023 and is expected to approach $200 billion over the next decade. Much of that growth is coming from what the industry calls Clinical Alignment, products meant to continue the logic of in-clinic treatment at home. Brands such as SkinCeuticals, Obagi and Medik8 have long worked in this space, but the concept is now spreading more widely.
One of the latest examples comes from Israel. Geneo, the brand known for facial treatments based on OxyGeneo technology, has launched its first home-care line, EverCare. The company says the goal is not just to sell skincare, but to extend the effect of the professional treatment so it lasts longer for the skin and the client.
The line includes Purehydra Serum, a moisturizing serum with hyaluronic acid, peptides and edelweiss extract; TruShine serum, for brightening the complexion with botanical ingredients and antioxidants; and EverYouth Cream, an anti-aging cream with peptides, vitamin E and papaya extract. The formulas are designed to work in synergy with Geneo’s oxy-pods, so a customer can continue treatment at home after a clinic visit. The article concludes that the esthetician no longer sees the skin only once a month, because the treatment now includes homework at home.
